Potential role of the 5-HT6 receptor in depression and anxiety: An overview of preclinical data

Pharmacological Reports

Volumn 62, Issue 4, 2010, Pages 564-577

  Wesołowska, Anna ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Anxiety; Depression; Hippocampus; Mice; Rats; Serotonin

Indexed keywords

1N (6 CHLOROIMIDAZO[2,1 B][1,3]THIAZOLE 5 SULFONYL)TRYPTAMINE; 2 ETHYL 5 METHOXY N,N DIMETHYLTRYPTAMINE; 2 [1 [(6 CHLOROIMIDAZO[2,1 B][1,3]THIAZOL 5 YL)SULFONYL] 1H INDOL 3 YL]N,N DIMETHYLETHANAMINE; 4 IODO N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL]BENZENESULFONAMIDE; 5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMFEBUTAMONE; AMINOGLUTETHIMIDE; AMITRIPTYLINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHLORAMPHETAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; DESIPRAMINE; DIAZEPAM; FLUOXETINE; IDAZOXAN; IMIPRAMINE; LY 586713; METYRAPONE; MIANSERIN; N (3,5 DICHLORO 2 METHOXYPHENYL) 4 METHOXY 3 (1 PIPERAZINYL)BENZENESULFONAMIDE; SB 258585; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; SEROTONIN AGONIST; SULPIRIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAY 181187; WAY 208466;

ALZHEIMER DISEASE; ANXIETY DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DRUG ANTAGONISM; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; HIPPOCAMPUS; HUMAN; LOW DRUG DOSE; MAJOR DEPRESSION; NONHUMAN; OBESITY; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SINGLE DRUG DOSE; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT;

EID: 77957983253     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70315-7     Document Type: Review

References (119)

1. 1B receptor knockout mice. J Neurochem, 2000, 75, 2415-2426.
2. 2+/calmodulin-sensitive adenylyl cyclases by the Gs-coupled 5-hydroxytryptamine subtype 5-HT7A receptor. J Biol Chem, 1998, 273, 17469-17476.
3. Balerio GN, Aso E, Maldonado R: Role of cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology, 2006, 184, 504-513.
4. Beck CH: Acute treatment with antidepressant drugs selectively increases the expression of c-fos in the rat brain. J Psychiatry Neurosci, 1995, 20, 25-23.
5. Benes FM, Burke RE, Walsh J, Berrette S, Matzilevich D, Minns M, Konradi C: Acute amygdalar activation induces an upregulation of multiple monoamine G protein coupled pathways in rat hippocampus. Mol Psychiatry, 2004, 9, 932-945.
6. Boast CA, Bernard PS, Barbaz BS, Bergen KM: The neuropharmacology of various diazepam antagonists. Neuropharmacology, 1983, 22, 1511-1521.
7. 6 receptors stably expressed in HEK293 cells. Neuropharmacology, 1997, 36, 713-720.
8. 3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum. Mol Pharmacol, 1998, 54, 577-583.
9. Bonasera SJ, Chu H-M, Brennan TJ, Tecott LH: A null mutation of the serotonin 6 receptor alters acute responses to ethanol. Neuropsychopharmacology, 2006, 31, 1801-1813.
10. Borsini F: Role of the serotonergic system in the forced swimming test. Neurosci Biobehav Rev, 1995, 19, 377-395.
11. Borsini F, Meli A: Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology, 1988, 94, 147-160.
12. Borsini F, Meli A: The forced swimming test: its contribution to the understanding of the mechanisms of action of antidepressants. Adv Biosci, 1990, 77, 63-76.
13. 6 receptors at the plasma membrane of neural cilia in the rat brain. Brain Res, 2000, 872, 271-275.
14. Brioni JD, O'Neill AB, Kim DJ, Decker MW: Nicotinic receptor agonists exhibits anxiolytic-like effects on the elevated plus-maze test. Eur J Pharmacol, 1993, 238, 1-8.
15. 6 receptor antagonist. J Med Chem, 1999, 42, 202-205.
16. 6 receptor antagonism. A novel mechanism for the management of obesity. SMI Inaugural Conference on Obesity and Related Disorders, 2003, London.
17. Chojnacka-Wójcik E, Kłodziñska A, Pilc A: Glutamate receptor ligands as anxiolytics. Curr Opin Investig Drugs, 2001, 2, 1112-1119.
18. 6 receptor agonist. J Med Chem, 2007, 50, 5535-5538.
19. Coppell AL, Pei Q, Zetterström TSC: Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology, 2003, 44, 903-910.
20. Cryan JF, Mombereau C, Vassout A: The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev, 2005, 29, 571-625.
21. 6 antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate. Br J Pharmacol, 2000, 130, 23-26.
22. 6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology, 2001, 25, 662-668.
23. 6 receptor antagonist. Brain Res Bull, 2003, 59, 513-521.
24. Degroot A, Treit D: Dorsal and ventral hippocampal cholinergic systems modulate anxiety in the plus-maze and shock-probe tests. Brain Res, 2002, 949, 60-70.
25. 125I]SB-258585. Synapse, 2002, 45, 191-199.
26. File SE, Pellow S, Wilks L: The sedative effects of CL 218,872, like those of chlordiazepoxide, are reversed by benzodiazepine antagonists. Psychopharmacology, 1985, 85, 295-300.
27. 6 receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology, 2004, 29, 93-100.
28. Fone KCF: The 5-ht6 receptor: potential CNS functions. Br J Pharmacol, 2000, 131, Suppl, 238P.
29. de Foubert G, Carney SL, Robinson CS, Destexhe EJ, Tomlinson R, Hicks CA, Murray TK et al.: Fluoxetineinduced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience, 2004, 128, 597-604.
30. 6-receptor activation on rat brain-derived neurotrophic factor and activity-regulated cytoskeletalassociated protein mRNA expression. Neuroscience, 2007, 147, 778-785.
31. 6 receptor antagonism potentiates the behavioral and neurochemical effects of amphetamine but not cocaine. Neuropharmacology, 2002, 42, 170-180.
32. 6 receptor-like material in the rat central nervous system. Brain Res, 1997, 23, 207-219.
33. 6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse, 1996, 23, 164-173.
34. 6 serotonin receptors. J Med Chem, 2000, 43, 1011-1018.
35. 6 receptors. Neuropsychopharmacology, 1999, 21, 68-76.
36. 6-R antagonists improve performance in an attentional set shifting tast in rats. Psychopharmacology, 2005, 181, 253-259.
37. 6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther, 2008, 117, 207-231.
38. Hensler JG: Serotonergic modulation of the limbic system. Neurosci Biobehav Rev, 2006, 30, 203-214.
39. 6 antagonists in the rat forced swimming test: Potential therapeutic utility in mood disorders associated with Alzheimer's disease. Life Sci, 2009, 84, 558-562.
40. Hirst WD, Abrahamsen B, Blaney FE, Calver AR, Aloj L, Price GW, Medhurst AD: Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol, 2003, 64, 1295-1308.
41. 6 receptors in rat, pig and human brain tissue. Br J Pharmacol, 2000, 130, 1597-1605.
42. 6 receptors. Br J Pharmacol, 1999, 127, 23P.
43. 6 receptor antagonist. Soc Neurosci Meet, 2003, Abstr. 576.7.
44. 6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol, 2006, 553, 109-119.
45. 1B receptor agonists. Pharmacol Biochem Behav, 2004, 77, 69-75.
46. Horowitz JM, Goyal A, Ramdeen N, Hallas BH, Horowitz AT, Torres G: Characterization of fluoxetine plus olanzapine treatment in rats: a behavior, endocrine, and immediate-early gene expression analysis. Synapse, 2003, 50, 353-364.
47. Integrity Database, Prous Science, 2007. (http://www.integrity. prous.com)
48. Investigational Drugs Database IDdb3, Thomson Current Drugs, 2007. (http://www.iddb3.com).
49. Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ: A cholinergic-adrenergic hypothesis of mania and depression. Lancet, 1972, 2, 632-635.
50. 6 receptor antagonists in rodent models of learning. Soc Neurosci Meeting, 2005, Abstr. 881.8.
51. 6 serotonin receptor and mutagenesis studies of the third cytoplasmatic loop. Brain Res Mol Brain Res, 2001, 90, 110-117.
52. 6 serotonin receptor. J Neurochem, 1996, 66, 47-56.
53. Kostowski W: Possible relationship of the locus coeruleus-hippocampal noradrenergic neurons to depression and mode of action of antidepressant drugs. Pol J Pharmacol Pharm, 1985, 37, 727-743.
54. Kramlinger KG, Petersen GC, Watson PK, Leonard LL: Metyrapone for depression and delirium secondary to Cushing's syndrome. Psychosomatics, 1985, 26, 67-71.
55. Kwon MO, Fischer F, Matthisson M, Herling P: List of drugs in development for neurodegenerative diseases. Update June 2004. Neurodegener Dis, 2004, 1, 113-154.
56. 6 receptor antagpnist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse, 2004, 51, 158-164.
57. Lange C, Irle E: Enlarged amygdala volume and reduced hippocampal volume in young women with major depression. Psychol Med, 2004, 324, 1059-1064.
58. Leung JWC, Xue H: GABAergic functions and depression: from clinical therapies to herbal medicine. Curr Drug Targets CNS Neurol Disord, 2003, 2, 363-373.
59. 6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain Res, 2007, 1134, 70-78.
60. 6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. Neuropsychopharmacology, 2005, 30, 2169-2179.
61. Liljequist S, Engel JA: The effects of GABA and benzodiazepine receptor antagonists on the anti-conflict actions of diazepam or ethanol. Pharmacol Biochem Behav, 1984, 21, 521-525.
62. 6) receptor antagonists in rodent models of learning. J Pharmacol Exp Ther, 2003, 307, 682-691.
63. 6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex. Psychopharmacology, 2008, 196, 93-104.
64. Malberg JE, Schechter LE: Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des, 2005, 11, 145-155.
65. 6 receptor-mediated acetylcholine release. Eur J Neurosci, 2006, 24, 1299-1306.
66. Millan MJ: The neurobiology and control of anxious states. Prog Neurobiol, 2003, 70, 83-244.
67. 6 receptors: a novel target for cognitive enhancement. Pharmacol Ther, 2005, 108, 320-333.
68. Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR: Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol, 1993, 43, 320-327.
69. Murphy BE, Dhar V, Ghadirian AM, Chouinard G, Keller R: Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol, 1991, 11, 121-126.
70. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM: Neurobiology of depression. Neuron, 2002, 34, 13-25.
71. Neumeister A, Wood S, Bonne O, Nugent AC, Luckenbaugh DA, Young T, Bain EE et al.: Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry, 2005, 57, 935-937.
72. O'Brien JT, Lloyd A, McKeith I, Gholkar A, Ferrier N: A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects. Am J Psychiatry, 2004, 161, 2081-2090.
73. Otano A, Frechilla D, Cobreros A, Cruz-Orive LM, Insausti A, Insausti R, Hamon M, Del Rio J: Anxiogeniclike effects and reduced stereological counting of immunolabelled 5-hydroxytryptamine6 receptors in rat nucleus accumbens by antisense oligonucleotides. Neuroscience, 1999, 92, 1001-1009.
74. Paul IA, Skolnick P: Glutamate and depression: Clinical and preclinical studies. Ann NY Acad Sci, 2003, 1003, 250-272.
75. Pei Q, Zetterström TSC, Sprakes ME, Tordera R, Sharp T: Antidepressant drug treatment induces Arc gene expression in the rat brain. Neuroscience, 2003, 121, 975-982.
76. Petty F: GABA and mood disorders: a brief review and hypothesis. J Affect Disord, 1995, 34, 275-281.
77. Pierce PA, Xie G-X, Levine JD, Peroutka SJ: 5-Hydroxytryptamine receptor subtype messenger RNAs in rat peripheral sensory and sympathetic ganglia: a polymerase chain reaction study. Neuroscience, 1996, 70, 553-559.
78. Plassat JL, Amlaiky N, Hen R: Molecular cloning of a mammalin serotonin receptor that activates adenylate cyclase. Mol Pharmacol, 1993, 44, 229-236.
79. Popik P, Kozela E, Krawczyk M: Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram. Br J Pharmacol, 2003, 139, 1196-1202.
80. Porsolt RD, Bertin A, Blavet N, Deniel M, Jalfre M: Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol, 1979, 57, 201-210.
81. Przegaliñski E, Tatarczyñska E, Dereñ-Wesołek A, Chojnacka-Wójcik E: Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology, 1997, 36, 31-37.
82. 6 antagonist MS-245. Pharmacol Biochem Behav, 2004, 78, 263-268.
83. 6 receptor antagonist. J Med Chem, 2003, 46, 1273-1276.
84. 125I]SB-258585. Brain Res, 2002, 934, 49-57.
85. 6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology, 2001, 158, 114-119.
86. 6 receptor antagonist. Br J Pharmacol, 2000, 130, 1606-1612.
87. 6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem Biophys Res Commun, 1993, 193, 268-276.
88. Russo-Neustadt AA, Chen MJ: Brain-derived neurotrophic factor and antidepressant activity. Curr Pharm Des, 2005, 11, 1495-1510.
89. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF: Subtypespecific alterations of γ-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry, 2004, 61, 705-713.
90. Sanacora G, Mason GF, Krystal JH: Impairment of GABAergic function in depression: new insights from neuroimaging. Crit Rev Neurobiol, 2000, 14, 23-45.
91. Sarter M, Parikh V: Choline transporters, cholinergic transmission and cognition. Nat Rev Neurosci, 2005, 6, 48-56.
92. Saylam C, Ucerler H, Kitis O, Ozand E, Gonul AS: Reduced hippocampal volume in drug-free depressed patients. Surg Radiol Anat, 2006, 28, 82-87.
93. 6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology, 2008, 33, 1323-1335.
94. 6 receptors positively coupled to adenylyl cyclase in striatal neurons in culture. NeuroReport, 1994, 5, 2553-2557.
95. Sherman AD, Allers GL: Relationship between regional distribution of imipramine and its effect on learned helplessness in the rat. Neuropharmacology, 1980, 19, 159-162.
96. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M et al.: Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry, 2003, 54, 70-75.
97. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS: Brain-derived neurotrophic factor produces antidepressant effects in behavioural models of depression. J Neurosci, 2002, 22, 3251-3261.
98. Shirazi-Southall S, Rodriguez DE, Nomikkos GG: Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hip-pocampus of the rat. Neuropsychopharmacology, 2002, 26, 583-594.
99. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR: Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry, 2002, 7, 525-535.
100. Stefujl J, Jernej B, Cicin-Sain L, Rinner I, Schauenstein K: mRNA expression of serotonin receptors incells of the immune tissues of the rat. Brain Behav Immun, 2000, 14, 219-224.
101. 6 receptor stimulation. J Neurosci, 2007, 27, 4201-4209.
102. Videbech P, Ravnkilde B: Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry, 2004, 161, 1957-1966.
103. 6] receptor gene in bipolar affective disorder and schizophrenia. Am J Med Genet, 2000, 96, 217-221.
104. Vythilingam M, Vermetten E, Anderson GM, Luckenbaugh D, Anderson ER, Snow J, Staib LH et al.: Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry, 2004, 56, 101-112.
105. 6 with neuropeptides in rat striatum. J Comp Neurol, 1996, 370, 405-414.
106. Ward RP, Hamblin MW, Lachowicz JE, Hoffman BJ, Sibley DR, Dorsa DM: Localization of serotonin subtype 6 receptor messenger RNAin the rat brain by in situ hybridization histochemistry. Neuroscience, 1995, 64, 1105-1111.
107. 6 receptor antagonist SB-399885 in rats. Pharmacol Rep, 2007, 59, 664-671.
108. 6 receptor antagonist SB-399885: the impact of benzodiazepine receptors. Eur J Pharmacol, 2008, 580, 355-260.
109. 6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology, 2007, 52, 1274-1283.
110. 6 receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats. Eur J Pharmacol, 2008, 582, 88-93.
111. 6 receptor antagonist SB-258585 after intrahippocampal administration to rats. Behav Pharmacol, 2007, 18, 439-446.
112. Winter H, Irle E: Hippocampal volume in adult burn patients with and without posttraumatic stress disorder. Am J Psychiatry, 2004, 16, 2194-2200.
113. Woolley ML, Bentley JC, Sleight AJ, Marsden CA, Fone KC: A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology, 2001, 41, 210-219.
114. 6 receptors. Curr Drug Targets CNS Neurol Disord, 2004, 3, 59-79.
115. Woods A, Smith C, Szewczak M, Dunn RW, Cornfeldt M, Corbett R: Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacology, 1993, 112, 195-198.
116. 6 and 5-HT7 receptor gene expression in the rat hippocampus. Mol Brain Res, 1997, 45, 182-186.
117. Yilmaz A, Schulz D, Aksoy A, Canbeyli R: Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav, 2002, 71, 341-344.
118. 6 receptor subtype in the rat brain. Life Sci, 1998, 62, 1473-1477.
119. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh MA, Charney DS, Manji HK: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 2006, 63, 856-864.